Drug Profile
BMS 817399
Alternative Names: BMS817399Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antirheumatics
- Mechanism of Action CCR1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 17 Jun 2013 Bristol-Myers Squibb completes a phase II trial in Rheumatoid arthritis in USA, Mexico, Argentina, South Korea, Spain, South Africa, and Russia (NCT01404585)
- 29 Nov 2011 Phase-II clinical trials in Rheumatoid arthritis in Mexico, Argentina, South Korea, Spain, South Africa, and Russia (PO)
- 31 Oct 2011 Phase-II clinical trials in Rheumatoid arthritis in USA (PO)